Move to topTop
May 19, 2015

Tokyo, Japan, May 19, 2015 -- Terumo Corporation and the French company Arterial Remodeling Technologies S.A. (ART) announced today that ART has received CE (Mark clearance in Europe for its Pure Bioresorbable Scaffold.

Through an agreement concluded between the companies in March 2014, Terumo acquired exclusive acquisition rights for the coronary drug eluting bioresorbable scaffold technology. The Pure Bioresorbable Scaffold developed by ART will serve as the platform for the next generation of coronary drug eluting bioresorbable scaffolds to be developed by Terumo.

The CE marking for the pure bioresorbable scaffold represents a major step forward for both companies' joint development of a drug-eluting bioresorbable scaffold through the application of the technology and is expected to contribute to accelerating this development in the future.

Jean Fajadet, MD, PhD, Co-Director of Interventional Cardiology at the Clinique Pasteur, in Toulouse, France, commented on the CE marking for the bioresorbable scaffold technology: "Bioresorbable scaffolds have the potential to address unmet needs in daily clinical practice in interventional cardiology."

Terumo and ART will be presenting the bioresorbable scaffold technology at EuroPCR, which is one of the best-known and largest interventional cardiology courses in Europe. The presentation is scheduled during the ART symposium that will be held on May 20, 2015.

About ART's bioresorbable scaffold technology

Bioresorbable scaffolds, which biodegrade and are resorbed inside the body, are currently attracting attention as a next-generation drug eluting stent technology. Since they do not remain inside the body like conventional metal stents, bioresorbable scaffolds are expected to reduce thrombosis and shorten the duration of antiplatelet therapy. Over five million stents are used worldwide each year. Drug-eluting bioresorbable scaffolds are anticipated to steadily replace them in the future.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.